LA JOLLA PHARMACEUTICAL'S PATENT ALLOWED
LA JOLLA PHARMACEUTICAL'S PATENT ALLOWED SAN DIEGO, April 2 /PRNewswire/ -- La Jolla Pharmaceutical Co.
announced today that it received notice of allowance from the U.S. Patent Office of a patent concerning its drug candidate for Systemic Lupus Erythematosus (SLE) based on the company's core technology of "B-Cell tolerance" for arresting the synthesis of antibodies. In SLE patients, anti-DNA antibodies are a hallmark of the disease and are considered to be responsible for chronic kidney disease. SLE is a debilitating, life-threatening disease that affects more than 200,000 individuals in the United States.
Joseph Stemler, the company's president, commented, "We are very pleased that this patent will issue shortly. It is the first of a group of pending applications covering the structure of tolerogens and the composition of our Lupus compound." La Jolla Pharmaceutical Co. was established in 1989 to develop products based on its proprietary antigen-polymer conjugate technology to treat antibody-mediated diseases. The company is privately held and is headquartered in San Diego. -0- 4/2/92 /CONTACT: Andrew Wiseman of La Jolla Pharmaceutical, 619-452-6600/ CO: La Jolla Pharmaceutical Co. ST: California IN: MTC SU:
AL -- SD001 -- 4214 04/02/92 09:02 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 2, 1992|
|Previous Article:||FLUOR CORP. ANNOUNCES REPURCHASE OF GREENVILLE CENTRE I|
|Next Article:||SHOPKO STORES REPORTS RECORD FOURTH QUARTER AND YEAR-END RESULTS|